Igor Barjaktarevic
Pulmonary Disease · Los Angeles, CANPI 1932345105
Payments from drug & device makers
Across 397 payments — averaging $4805.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$392K
- Roche Products Limited$323K
- Amgen$267K
- Takeda Pharmaceuticals U.S.A., Inc.$245K
- Grifols Therapeutics LLC$124K
- Genentech, Inc.$81K
- plus $475K from 19 others
Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$250
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 80 | $392,324 |
| Roche Products Limited | 13 | $323,252 |
| Amgen | 2 | $267,333 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $244,732 |
| Grifols Therapeutics LLC | 3 | $124,172 |
| Genentech, Inc. | 9 | $81,281 |
| Sanofi | 29 | $69,650 |
| AstraZeneca | 47 | $67,294 |
| Viatris Specialty LLC | 2 | $62,676 |
| Grifols USA, LLC | 59 | $59,834 |
| Vertex | 14 | $59,031 |
| Grifols Biologicals LLC | 1 | $31,781 |
| GSK | 21 | $22,150 |
| CSL Behring | 5 | $18,048 |
| GE HealthCare | 12 | $16,710 |
| Verona Pharma, Inc. | 12 | $15,350 |
| Shire North American Group Inc | 28 | $14,810 |
| Regeneron | 7 | $11,111 |
| Genentech USA, Inc. | 8 | $7,804 |
| Astrazeneca UK Limited | 2 | $6,981 |
| Regeneron Healthcare Solutions, Inc. | 6 | $4,483 |
| Aero US Inc | 2 | $3,306 |
| Grifols Shared Services North America, Inc. | 1 | $2,460 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,200 |
| Pulmonx Corporation | 1 | $16 |
How this compares
$1,907,791 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Rajan SaggarLos Angeles$3.3M
- Stephen Samuel WeigtLos Angeles$2.1M
- Robert WolfeLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- Victor TapsonLos Angeles$931K
- John BelperioLos Angeles$905K
- Sivagini GaneshLos Angeles$816K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.